|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Morgan E, Arnold M, Gini A, Lorenzoni V,
Cabasag CJ, Laversanne M, Vignat J, Ferlay J, Murphy N and Bray F:
Global burden of colorectal cancer in 2020 and 2040: Incidence and
mortality estimates from GLOBOCAN. Gut. 72:338–344. 2023.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Siegel RL, Wagle NS, Cercek A, Smith RA
and Jemal A: Colorectal cancer statistics, 2023. CA Cancer J Clin.
73:233–254. 2023.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Van Cutsem E, Cervantes A, Adam R, Sobrero
A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson
A, Bodoky G, et al: ESMO consensus guidelines for the management of
patients with metastatic colorectal cancer. Ann Oncol.
27:1386–1422. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Douillard JY, Oliner KS, Siena S,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, et al: Panitumumab-FOLFOX4 treatment and RAS mutations
in colorectal cancer. N Engl J Med. 369:1023–1034. 2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Bokemeyer C, Köhne CH, Ciardiello F, Lenz
HJ, Heinemann V, Klinkhardt U, Beier F, Duecker K, van Krieken JH
and Tejpar S: FOLFOX4 plus cetuximab treatment and RAS mutations in
colorectal cancer. Eur J Cancer. 51:1243–1252. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Heinemann V, von Weikersthal LF, Decker T,
Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller
C, Kahl C, Seipelt G, et al: FOLFIRI plus cetuximab versus FOLFIRI
plus bevacizumab as first-line treatment for patients with
metastatic colorectal cancer (FIRE-3): A randomised, open-label,
phase 3 trial. Lancet Oncol. 15:1065–1075. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Venook AP, Niedzwiecki D, Lenz HJ,
Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH,
Atkins JN, et al: Effect of first-line chemotherapy combined with
cetuximab or bevacizumab on overall survival in patients with KRAS
wild-type advanced or metastatic colorectal cancer: A randomized
clinical trial. JAMA. 317:2392–2401. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Tsai HL, Huang CW, Lin YW, Wang JH, Wu CC,
Sung YC, Chen TL, Wang HM, Tang HC, Chen JB, et al: Determination
of the UGT1A1 polymorphism as guidance for irinotecan dose
escalation in metastatic colorectal cancer treated with first-line
bevacizumab and FOLFIRI (PURE FIST). Eur J Cancer. 138:19–29.
2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Wang F, He MM, Xiao J, Zhang YQ, Yuan XL,
Fang WJ, Zhang Y, Wang W, Hu XH, Ma ZG, et al: A Randomized,
open-label, multicenter, phase 3 study of high-dose vitamin C plus
FOLFOX ± bevacizumab versus FOLFOX ± bevacizumab in unresectable
untreated metastatic colorectal cancer (VITALITY study). Clin
Cancer Res. 28:4232–4239. 2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Cremolini C, Schirripa M, Antoniotti C,
Moretto R, Salvatore L, Masi G, Falcone A and Loupakis F:
First-line chemotherapy for mCRC-a review and evidence-based
algorithm. Nat Rev Clin Oncol. 12:607–619. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Goldstein DA, Chen Q, Ayer T, Howard DH,
Lipscomb J, El-Rayes BF and Flowers CR: First- and second-line
bevacizumab in addition to chemotherapy for metastatic colorectal
cancer: A United States-based cost-effectiveness analysis. J Clin
Oncol. 33:1112–1118. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Watanabe J, Muro K, Shitara K, Yamazaki K,
Shiozawa M, Ohori H, Takashima A, Yokota M, Makiyama A, Akazawa N,
et al: Panitumumab vs bevacizumab added to standard first-line
chemotherapy and overall survival among patients with RAS
Wild-type, left-sided metastatic colorectal cancer: A randomized
clinical trial. JAMA. 329:1271–1282. 2023.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Qin S, Li J, Wang L, Xu J, Cheng Y, Bai Y,
Li W, Xu N, Lin LZ, Wu Q, et al: Efficacy and tolerability of
first-line cetuximab plus leucovorin, fluorouracil, and oxaliplatin
(FOLFOX-4) versus FOLFOX-4 in patients with RAS wild-type
metastatic colorectal cancer: The open-label, randomized, phase III
TAILOR trial. J Clin Oncol. 36:3031–3039. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Douillard JY, Siena S, Cassidy J,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, et al: Final results from PRIME: Randomized phase III
study of panitumumab with FOLFOX4 for first-line treatment of
metastatic colorectal cancer. Ann Oncol. 25:1346–1355.
2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Bond MJG, Bolhuis K, Loosveld OJL, de
Groot JWB, Droogendijk H, Helgason HH, Hendriks MP, Klaase JM,
Kazemier G, Liem MSL, et al: First-line systemic treatment
strategies in patients with initially unresectable colorectal
cancer liver metastases (CAIRO5): An open-label, multicentre,
randomised, controlled, phase 3 study from the Dutch colorectal
cancer group. Lancet Oncol. 24:757–771. 2023.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Arnold D, Lueza B, Douillard JY, Peeters
M, Lenz HJ, Venook A, Heinemann V, Van Cutsem E, Pignon JP,
Tabernero J, et al: Prognostic and predictive value of primary
tumour side in patients with RAS wild-type metastatic colorectal
cancer treated with chemotherapy and EGFR directed antibodies in
six randomized trials. Ann Oncol. 28:1713–1729. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Holch JW, Ricard I, Stintzing S, Modest DP
and Heinemann V: The relevance of primary tumour location in
patients with metastatic colorectal cancer: A meta-analysis of
first-line clinical trials. Eur J Cancer. 70:87–98. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Mills EJ, Thorlund K and Ioannidis JPA:
Demystifying trial networks and network meta-analysis. BMJ.
346(f2914)2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Lumley T: Network meta-analysis for
indirect treatment comparisons. Stat Med. 21:2313–2324.
2002.PubMed/NCBI View
Article : Google Scholar
|
|
21
|
Jansen JP, Trikalinos T, Cappelleri JC,
Daw J, Andes S, Eldessouki R and Salanti G: Indirect treatment
comparison/network meta-analysis study questionnaire to assess
relevance and credibility to inform health care decision making: An
ISPOR-AMCP-NPC good practice Task Force report. Value Health.
17:157–173. 2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Higgins JP, Altman DG, Gøtzsche PC, Jüni
P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, et
al: The Cochrane Collaboration's tool for assessing risk of bias in
randomised trials. BMJ. 343(d5928)2011.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Balduzzi S, Rücker G, Nikolakopoulou A,
Papakonstantinou T, Salanti G, Efthimiou O and Schwarzer G:
netmeta: An R package for network meta-analysis using frequentist
methods. J Stat Softw. 106:1–40. 2023.
|
|
24
|
Lonardi S, Rasola C, Lobefaro R, Rossini
D, Formica V, Scartozzi M, Frassineti GL, Boscolo G, Cinieri S, Di
Donato S, et al: Initial panitumumab plus fluorouracil, leucovorin,
and oxaliplatin or plus fluorouracil and leucovorin in elderly
patients with RAS and BRAF wild-type metastatic colorectal cancer:
The PANDA trial by the GONO foundation. J Clin Oncol. 41:5263–5273.
2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Boige V, Blons H, François E, Ben
Abdelghani M, Phelip JM, Le Brun-Ly V, Mineur L, Galais MP, Villing
AL, Hautefeuille V, et al: Maintenance therapy with cetuximab after
FOLFIRI plus cetuximab for RAS wild-type metastatic colorectal
cancer: A phase 2 randomized clinical trial. JAMA Netw Open.
6(e2333533)2023.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Aranda E, García-Alfonso P, Benavides M,
Sánchez Ruiz A, Guillén-Ponce C, Safont MJ, Alcaide J, Gómez A,
López R, Manzano JL, et al: First-line mFOLFOX plus cetuximab
followed by mFOLFOX plus cetuximab or single-agent cetuximab as
maintenance therapy in patients with metastatic colorectal cancer:
Phase II randomised MACRO2 TTD study. Eur J Cancer. 101:263–272.
2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Modest DP, Martens UM, Riera-Knorrenschild
J, Greeve J, Florschütz A, Wessendorf S, Ettrich T, Kanzler S,
Nörenberg D, Ricke J, et al: FOLFOXIRI plus panitumumab as
first-line treatment of RAS wild-type metastatic colorectal cancer:
The randomized, open-label, phase II VOLFI study (AIO KRK0109). J
Clin Oncol. 37:3401–3411. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Modest DP, Karthaus M, Fruehauf S, Graeven
U, Müller L, König AO, Fischer von Weikersthal L, Caca K,
Kretzschmar A, Goekkurt E, et al: Panitumumab plus fluorouracil and
folinic acid versus fluorouracil and folinic acid alone as
maintenance therapy in RAS wild-type metastatic colorectal cancer:
The randomized PANAMA trial (AIO KRK 0212). J Clin Oncol. 40:72–82.
2022.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Liu R, Yin X, Bai Y, Zhong H, Ye F, Wang
Q, Liu M, Li N, Deng Y, Wang Y, et al: A140 plus mFOLFOX6 compared
with cetuximab plus mFOLFOX6 for first-line RAS wild-type
metastatic colorectal cancer: A randomized clinical trial. Eur J
Cancer. 226(115566)2025.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Shi Y, Ba Y, Wang J, Xiong J, Gu K, Chen
Y, Zheng Z, Wang Z, Guo W, Cheng Y, et al: First-line treatment of
anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus
FOLFIRI alone in Chinese patients with RAS/BRAF wild-type
metastatic colorectal cancer: A randomized, phase 3 trial. Signal
Transduct Target Ther. 10(147)2025.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Misale S, Di Nicolantonio F,
Sartore-Bianchi A, Siena S and Bardelli A: Resistance to anti-EGFR
therapy in colorectal cancer: From heterogeneity to convergent
evolution. Cancer Discov. 4:1269–1280. 2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Parseghian CM, Napolitano S, Loree JM and
Kopetz S: Mechanisms of innate and acquired resistance to anti-EGFR
therapy: A review of current knowledge with a focus on rechallenge
therapies. Clin Cancer Res. 25:6899–6908. 2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Innocenti F, Schilsky RL, Ramírez J,
Janisch L, Undevia S, House LK, Das S, Wu K, Turcich M, Marsh R, et
al: Dose-finding and pharmacokinetic study to optimize the dosing
of irinotecan according to the UGT1A1 genotype of patients with
cancer. J Clin Oncol. 32:2328–2334. 2014.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Jain RK: Normalization of tumor
vasculature: An emerging concept in antiangiogenic therapy.
Science. 307:58–62. 2005.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Pietrantonio F, Cremolini C, Petrelli F,
Di Bartolomeo M, Loupakis F, Maggi C, Antoniotti C, de Braud F,
Falcone A and Iacovelli R: First-line anti-EGFR monoclonal
antibodies in panRAS wild-type metastatic colorectal cancer: A
systematic review and meta-analysis. Crit Rev Oncol Hematol.
96:156–166. 2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Toffoli G, Sharma MR, Marangon E, Posocco
B, Gray E, Mai Q, Buonadonna A, Polite BN, Miolo G, Tabaro G and
Innocenti F: Genotype-guided dosing study of FOLFIRI plus
bevacizumab in patients with metastatic colorectal cancer. Clin
Cancer Res. 23:918–924. 2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Tejpar S, Stintzing S, Ciardiello F,
Tabernero J, Van Cutsem E, Beier F, Esser R, Lenz HJ and Heinemann
V: Prognostic and predictive relevance of primary tumor location in
patients with RAS wild-type metastatic colorectal cancer:
Retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA
Oncol. 3:194–201. 2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Franke AJ, Skelton WP, Starr JS, Parekh H,
Lee JJ, Overman MJ, Allegra C and George TJ: Immunotherapy for
colorectal cancer: A review of current and novel therapeutic
approaches. J Natl Cancer Inst. 111:1131–1141. 2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Tabernero J, Vyas M, Giuliani R, Arnold D,
Cardoso F, Casali PG, Cervantes A, Eggermont AMM, Eniu A, Jassem J,
et al: Biosimilars: A position paper of the European society for
medical oncology, with particular reference to oncology
prescribers. ESMO Open. 1(e000142)2017.PubMed/NCBI View Article : Google Scholar
|
